Recent Progress in Immunotherapy for Gastric Cancer

Yoon, Jeesun; Kim, Tae-Yong; Oh, Do‐Youn

doi:10.5230/jgc.2023.23.e10

Cited by 13 publications

(6 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This progress has been driven by the discovery of innovative diagnostic biomarkers, the development of drugs targeting novel molecules, and the emergence of combination therapies, such as immunotherapy combined with chemotherapy, antiangiogenic agents, anti-HER-2 antibodies, and chemotherapy ( 26 ). Despite these advancements, a portion of GC patients do not derive benefits from immunotherapy, as evidenced by the lack of improvement in their OS and PFS compared to chemotherapy alone ( 28 ).…”

Section: Discussionmentioning

confidence: 99%

Interpretable machine learning for predicting the response duration to Sintilimab plus chemotherapy in patients with advanced gastric or gastroesophageal junction cancer

Wang,

Xu,

Cheng

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundSintilimab plus chemotherapy has proven effective as a combination immunotherapy for patients with advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC). A multi-center study conducted in China revealed a median progression-free survival (PFS) of 7.1 months. However, the prediction of response duration to this immunotherapy has not been thoroughly investigated. Additionally, the potential of baseline laboratory features in predicting PFS remains largely unexplored. Therefore, we developed an interpretable machine learning (ML) framework, iPFS-SC, aimed at predicting PFS using baseline (pre-treatment) laboratory features and providing interpretations of the predictions.Materials and methodsA cohort of 146 patients with advanced GC/GEJC, along with their baseline laboratory features, was included in the iPFS-SC framework. Through a forward feature selection process, predictive baseline features were identified, and four ML algorithms were developed to categorize PFS duration based on a threshold of 7.1 months. Furthermore, we employed explainable artificial intelligence (XAI) methodologies to elucidate the relationship between features and model predictions.ResultsThe findings demonstrated that LightGBM achieved an accuracy of 0.70 in predicting PFS for advanced GC/GEJC patients. Furthermore, an F1-score of 0.77 was attained for identifying patients with PFS durations shorter than 7.1 months. Through the feature selection process, we identified 11 predictive features. Additionally, our framework facilitated the discovery of relationships between laboratory features and PFS.ConclusionA ML-based framework was developed to predict Sintilimab plus chemotherapy response duration with high accuracy. The suggested predictive features are easily accessible through routine laboratory tests. Furthermore, XAI techniques offer comprehensive explanations, both at the global and individual level, regarding PFS predictions. This framework enables patients to better understand their treatment plans, while clinicians can customize therapeutic approaches based on the explanations provided by the model.

show abstract

Section: Discussionmentioning

confidence: 99%

Interpretable machine learning for predicting the response duration to Sintilimab plus chemotherapy in patients with advanced gastric or gastroesophageal junction cancer

Wang,

Xu,

Cheng

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Treatment modalities that should be applied after ICI combination therapy, such as re-administration of ICI or the use of combination therapy with drugs that have a different mechanism of action, are the subject of intensive research. Several clinical studies are ongoing to apply this therapeutic strategy perioperatively and/or postoperatively in patients with early GC[ 51 ]. Satisfactory results are obtained from the combination of ICI and chemotherapy with tolerable toxicity.…”

Section: Treatment Modalitiesmentioning

confidence: 99%

Immunotherapy of gastric cancer: Present status and future perspectives

Triantafillidis,

Konstadoulakis,

Papalois

2024

World J Gastroenterol

View full text Add to dashboard Cite

In this editorial, we comment on the article entitled “Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023),” which was published in the recent issue of the World Journal of Gastroenterology . We focused on the results of the authors’ bibliometric analysis concerning gastric cancer immunotherapy, which they analyzed in depth by compiling the relevant publications of the last 20 years. Before that, we briefly describe the most recent data concerning the epidemiological parameters of gastric cancer (GC) in different countries, attempting to give an interpretation based on the etiological factors involved in the etiopathogenesis of the neoplasm. We then briefly discuss the conservative treatment (chemotherapy) of the various forms of this malignant neoplasm. We describe the treatment of resectable tumors, locally advanced neoplasms, and unresectable (advanced) cases. Special attention is given to modern therapeutic approaches with emphasis on immunotherapy, which seems to be the future of GC treatment, especially in combination with chemotherapy. There is also a thorough analysis of the results of the study under review in terms of the number of scientific publications, the countries in which the studies were conducted, the authors, and the scientific centers of origin, as well as the clinical studies in progress. Finally, an attempt is made to draw some con-clusions and to point out possible future directions.

show abstract

“…Gastric cancer (GC) is the fourth leading cause of cancer-related deaths worldwide and the fifth most frequently diagnosed malignancy ( 1 ). South American and Asian nations account for the majority of new diagnoses of stomach cancer each year ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Current therapies and progress in the treatment of advanced gastric cancer

Li,

Shen,

Wang

2024

Front. Oncol.

View full text Add to dashboard Cite

Gastric cancer (GC) remains one of the most life-threatening disease worldwide with poor prognosis because of the absence of effective treatment and the delay in diagnosis. Due to the delay of diagnosis, a large proportion of GC patients are diagnosed as advanced GC, with extreme short lifespan. In the past few years, some pivotal progress and novel therapies was proposed, and conducted into clinical researches and practice. In this study, we summarized the development of several novel immunotherapy or targeted treatment modalities for advanced GC, including immune checkpoint inhibitors, anti-angiogenic therapy and cancer vaccines. Additionally, the advantage and potential weakness in each of these therapeutic methods are also listed. Finally, we discussed the promising research direction of advanced GC treatment, and the limitation in basic and clinical research of advanced GC, including the combination of immunotherapy and targeted therapy.

show abstract

Recent Progress in Immunotherapy for Gastric Cancer

Cited by 13 publications

References 63 publications

Interpretable machine learning for predicting the response duration to Sintilimab plus chemotherapy in patients with advanced gastric or gastroesophageal junction cancer

Interpretable machine learning for predicting the response duration to Sintilimab plus chemotherapy in patients with advanced gastric or gastroesophageal junction cancer

Immunotherapy of gastric cancer: Present status and future perspectives

Current therapies and progress in the treatment of advanced gastric cancer

Contact Info

Product

Resources

About